Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL

You may be eligible if

• Patients who underwent curative resection of primary tumor
• Pathologically confirmed CD20 positive diffuse large B-cell lymphoma (DLBCL) after surgical resection
• Ann Arbor Stage I or II
• No history of chemotherapy
• Performance status: ECOG 0-2
• Age: 18 to 70 years old
• Complete excision with negative resection margin on pathologic report after surgery
• Cardiac ejection fraction ≥ 50% as measured by MUGA or 2D echocardiography without clinically significant abnormalities
• Adequate renal function: serum creatinine level below 2 mg/dL (177μmol/L)
• Adequate liver functions: Transaminase (AST/ALT) \< 3X upper normal value, Bilirubin \< 2X upper normal value
• Adequate hematologic function: hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥ 1,500/mm3 and platelet count ≥ 75,000/mm3
• Informed consent
• Previous or concurrent cancer that is distinct in primary site or histology from DLBCL, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis \& T1). Any cancer curatively treated \> 3 years prior to entry is permitted
• Pregnant or lactating women, women of childbearing potential not employing adequate contraception
• Other serious illness or medical conditions
• 1. Unstable cardiac disease (i.e. congestive heart failure, arrhythmia symptomatic coronary artery disease) despite treatment, myocardial infarction within 6 months prior to study entry
• 2. History of significant neurological or psychiatric disorders including dementia or seizures
• 3. Active uncontrolled infection (viral, bacterial or fungal infection)
• 4. Other serious medical illnesses
• Known hypersensitivity to any of the study drugs or their ingredients
• Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy
• Patient with B symptoms or Bulky disease